Chart Of The Day: Another Money Losing Biotech Gets Crushed

Anthera Pharmaceuticals (ANTH) plummeted -65% after it said its Phase 3 study of its Sulloura drug in cystic fibrosis patients with exocrine pancreatic insufficiency missed its primary endpoint.